Thus, the analysis of different lesions in the same patient clearly indicates that in many cases cells with mutant BRAF coexist with cancer cells lacking BRAF mutations; the BRAF wild-type tumor cells are completely unaffected by targeted BRAF treatment, and thus greatly contribute to drug resistance [22]. The gene discussed is BRAF; the disease is neoplasm.